(Reuters) - Bristol-Myers Squibb Co's top shareholder Wellington Management said on Wednesday that it did not support the U.S. drugmaker's $74 billion purchase of biotech Celgene Corp, saying the deal is too risky. Wellington Management owns about 8 percent of Bristol-Myers shares and was the largest institutional holder as of Feb.
from Latest News Business on Firstpost https://ift.tt/2IHA2B9
Thursday, 28 February 2019
Top Bristol-Myers shareholder does not support $74 billion Celgene deal
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment